Research
Phase 2 afatinib results and other chordoma advances emerge from ASCO
7/8/2024
The trial results demonstrate that a subset of chordoma patients benefit from afatinib for a sustained period, and create an urgent need to identify biomarkers that can predict a response to EGFR inhibitors.
View Post